Zynteglo Advocates Accuse UK HTA Body Of Failing To 'Understand Patients' Lived Experience’

The UK Thalassaemia Society says that HTA body NICE fails to properly incorporate patient experiences into its decision making and that its patient engagement processes need reform. The marketing of Zynteglo, the gene therapy from bluebird bio for which the group is advocating, has just been temporarily suspended.